Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorothee Speiser

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
BMC Cancer|March 9, 2018
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer historyChristoph Engel, Kerstin Rhiem, Eric Hahnen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|November 22, 2024
Calculating Future 10-Year Breast Cancer Risks in Risk-Adapted Surveillance: A Method Comparison and Application in Clinical PracticeSilke Zachariae, Anne S Quante, Marion Kiechle, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2026
Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancerNatalie Herold, Christoph Engel, Dorothee Speiser, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
International Journal of Cancer|May 14, 2019
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillanceChristoph Engel, Christine Fischer, Silke Zachariae, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
BMC Cancer|March 9, 2018
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer historyChristoph Engel, Kerstin Rhiem, Eric Hahnen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|November 22, 2024
Calculating Future 10-Year Breast Cancer Risks in Risk-Adapted Surveillance: A Method Comparison and Application in Clinical PracticeSilke Zachariae, Anne S Quante, Marion Kiechle, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2026
Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancerNatalie Herold, Christoph Engel, Dorothee Speiser, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
International Journal of Cancer|May 14, 2019
Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillanceChristoph Engel, Christine Fischer, Silke Zachariae, et al.
Pageof 5